Completed PHASE1 INTERVENTIONAL 1-arm NCT02129933

VEGF-targeted Fluorescence Near-Infrared (NIR) Endoscopy in (Pre)Malignant Esophageal Lesions (VICE)

A Pilot Intervention Study for the Use of VEGF-targeted Fluorescence Near-Infrared (NIR) Endoscopy in (Pre)Malignant Esophageal Lesions

Sponsor: University Medical Center Groningen

Conditions Dysplasia Esophageal Cancer

Interventions Bevacizumab-IRDye800CW Near infrared fluorescence endoscopy platform

Updated 6 times since 2017 Last updated: Apr 14, 2024 Started: Apr 30, 2014 Primary completion: Nov 30, 2016 Completion: Nov 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02129933, this PHASE1 trial focuses on Dysplasia and Esophageal Cancer and remains completed. Sponsored by University Medical Center Groningen, it has been updated 6 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
May 2024 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — May 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Medical Center Groningen

Data source: University Medical Center Groningen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Groningen, Netherlands